Apogee Therapeutics, Inc. Common Stock Income Statement
Concept
Total Revenue
YoY
Cost of Goods Sold (COGS)
Gross Profit
Operating expenses
Selling, General & Administrative
Research & Development
Operating Income
Interest Expense
Income Before Tax
Tax Provision
Net Income
YoY
Total Expenses
Net Interest Income
EBITDA
Reconciled Depreciation
EBIT
2023
2022
0M
-
0M
0M
93M
25M
68M
-93M
0M
-84M
0M
-84M
111.10%
93M
9M
-93M
0M
0M
0M
-
0M
0M
31M
3M
28M
-31M
9M
-40M
0M
-40M
111.10%
31M
-9M
-31M
0M
0M
Concept
Total Revenue
YoY
Cost of Goods Sold (COGS)
Gross Profit
Operating expenses
Selling, General & Administrative
Research & Development
Operating Income
Interest Expense
Income Before Tax
Tax Provision
Net Income
YoY
Total Expenses
Net Interest Income
EBITDA
Reconciled Depreciation
EBIT
4Q2023
3Q2023
2Q2023
1Q2023
4Q2022
3Q2022
2Q2022
1Q2022
0M
-
0M
0M
37M
8M
29M
-37M
0M
-32M
0M
-32M
126.57%
37M
5M
-37M
0M
0M
0M
-
0M
0M
24M
7M
17M
-24M
0M
-21M
0M
-21M
6.02%
24M
3M
-21M
0M
-24M
0M
-
0M
0M
19M
5M
14M
-19M
0M
-19M
0M
-19M
6.02%
19M
0M
-19M
0M
-19M
0M
-
0M
0M
13M
4M
8M
-13M
0M
-13M
0M
-13M
6.02%
13M
0M
-13M
0M
0M
0M
-
0M
0M
14M
2M
12M
-14M
0M
-14M
0M
-14M
6.02%
14M
0M
-14M
0M
-14M
0M
-
0M
0M
11M
1M
10M
-11M
9M
-20M
0M
-20M
6.02%
11M
0M
-11M
0M
0M
0M
-
0M
0M
0M
0M
0M
0M
0M
0M
0M
0M
6.02%
0M
0M
0M
0M
-2M
0M
-
0M
0M
0M
0M
0M
0M
0M
0M
0M
0M
6.02%
0M
0M
0M
0M
0M